News
CYCCP
12.61
-6.59%
-0.89
Weekly Report: what happened at CYCCP last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at CYCCP last week (0408-0412)?
Weekly Report · 04/15 09:38
12 Health Care Stocks Moving In Friday's Intraday Session
PaxMedica stock increased by 110.9% to $0.87 during Friday's regular session. Q32 Bio (NASDAQ:QTTB) shares rose 23.89% during the session. Cyclacel Pharmaceuticals shares increased by 20.45%. SenesTech and Motus GI Hldgs were among the losers.
Benzinga · 04/12 16:31
Weekly Report: what happened at CYCCP last week (0401-0405)?
Weekly Report · 04/08 09:40
Cyclacel Pharmaceuticals To Present New Clinical Data At 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential As A Precision Medicine For Cancer
New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma. Cyclacel Pharmaceuticals, Inc. Is a biopharmaceutical company developing innovative medicines based on cancer cell biology. New data from the CYC065-101 study will be presented at the American Society of Clinical Oncology in 2024.
Benzinga · 04/01 13:16
Weekly Report: what happened at CYCCP last week (0325-0329)?
Weekly Report · 04/01 09:40
Weekly Report: what happened at CYCCP last week (0318-0322)?
Weekly Report · 03/25 09:41
Weekly Report: what happened at CYCCP last week (0311-0315)?
Weekly Report · 03/18 09:40
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
Cyclacel Pharmaceuticals, Inc. Will announce fourth quarter and full year 2023 financial results on March 19, 2024. The company is a biopharmaceutical company developing innovative medicines based on cancer cell biology. The Company will host a conference call on the same day.
Barchart · 03/13 15:05
Weekly Report: what happened at CYCCP last week (0304-0308)?
Weekly Report · 03/11 09:39
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
Cyclacel Pharmaceuticals, Inc. Received £2.3 million as a research & development tax credit from HMRC. The tax credit is based on R&D costs incurred in the year ended December 31, 2023. The company is developing innovative medicines based on cancer cell biology.
Barchart · 03/06 08:15
Weekly Report: what happened at CYCCP last week (0226-0301)?
Weekly Report · 03/04 09:40
Cyclacel Pharmaceuticals Inc <CYCC.OQ> expected to post a loss of $5.89 a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of $5.89 a share - Earnings Preview. The company is expected to show change in quarterly revenue when it reports results on March 4. Average analyst rating on the shares is "buy"
Reuters · 03/01 11:06
Weekly Report: what happened at CYCCP last week (0219-0223)?
Weekly Report · 02/26 09:44
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
Cyclacel Pharmaceuticals, Inc. Is a biopharmaceutical company developing innovative medicines based on cancer cell biology. Spiro Rombotis is scheduled to present at the 2024 BIO CEO & Investor Conference in-person at the New York Marriott Marquis on February 26-27, 2024.
Barchart · 02/20 08:15
Weekly Report: what happened at CYCCP last week (0212-0216)?
Weekly Report · 02/19 09:44
Weekly Report: what happened at CYCCP last week (0205-0209)?
Weekly Report · 02/12 09:41
Weekly Report: what happened at CYCCP last week (0129-0202)?
Weekly Report · 02/05 09:44
Weekly Report: what happened at CYCCP last week (0122-0126)?
Weekly Report · 01/29 09:40
Weekly Report: what happened at CYCCP last week (0115-0119)?
Weekly Report · 01/22 09:42
More
Webull provides a variety of real-time CYCCP stock news. You can receive the latest news about Cyclacel Phar Pr through multiple platforms. This information may help you make smarter investment decisions.
About CYCCP
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.